mutation as detected by an FDA-approved test. Please click here for Important Safety Information and Full Prescribing Information, including Boxed WARNING, for REZLIDHIA. About GAVRETO®GAVRETO ...

Rigel Therapeutics has expanded its oncology portfolio with REZLIDHIA and GAVRETO, alongside its original molecule TAVALISSE for chronic immune thrombocytopenia. The company’s IRAK1/4 inhibitor ...

The company is also making good progress with its second FDA-approved product, Rezlidhia (olutasidenib). The drug is ...

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) is expected to be issuing its quarterly earnings data after the market closes on Tuesday, March 4th. Analysts expect the company to announce ...